LISATA THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
110 ALLEN ROAD, BASKING RIDGE, NJ, 07920
Mailing Address
110 ALLEN ROAD, BASKING RIDGE, NJ, 07920
Phone
908-229-2590
Fiscal Year End
1231
EIN
222343568
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 3, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 8-K Current report of material events | January 27, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Completed patient enrollment in Phase 2 clinical trial for its lead drug candidate, a significant step towards market entry.
- Initiated a new Phase 1b clinical trial for another drug candidate, expanding its pipeline and exploring new therapeutic avenues.
Material Events
8-K
Strategy Change
January 27, 2026
High Impact
- Lisata Therapeutics has reclaimed full development and commercialization rights for certepetide in Greater China.
- This provides Lisata with strategic flexibility to redefine the drug's pathway in a key market.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.